44
45
Hassett JD 8 (1996) Anaerobic production of alginat by Pseudomonas aeruginosa:
Alginat restricts diffusion of oxygen. J Bacteriol 178:7322-7325.
Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron SD, Harbour C (2005) Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic and biofilm conditions. J Clin Microbiol 43:5085-5090.
Hoffman LR, Ramsey BW (2013) Cystic Fibrosis therapeutics: the road ahead. Chest.
143:207-213.
Kerem BS, Rommens JM, Buchannan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui L-C (1989) Identification of the cystic fibrosis gene: genetic analysis.
Science 245:1073-1080.
McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Döring G, Lee JC, Goldmann DA, Pier GB (1999) Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284:1523-1527.
O’May CY, Reid DW, Kirov SM. Anaerobic culture conditions favor biofilm-like phenotypes in Pseudomonas aeruginosa isolates from patients with cystic fibrosis (2006) FEMS Immunol Med Microbiol 48:373-380.
Olson AB, Sibley CD, Schmidt L, Wilcox MA, Surette MG, Corbett CR (2010) Development of real-time PCR assays for detection of the Streptococcus milleri group from cystic fibrosis clinical specimens by targeting the cnp60 and 16S rRNA genes. J Clin Microbiol 48:1150-1160.
Oxoid Microbiology Products (10.12.2013) MacConkey Agar No. 3, http://www.oxoid.com/UK/blue/prod_detail
Park MK, Myers RAM, Marzella L (1992) Oxygen tensions and infections: Modulation of microbial growth, activity of antimicrobial agents, and immunologic response. Clin Infect Dis 14:720-740.
Ratjen F, Döring G (2003) Cystic fibrosis. Lancet 361:681-689.
46
Rintelen C, Borneff-Lipp M, Worlitzsch D (2008) Strikt anaerobe Bakterien im Sputum von Kindern mit Cystischer Fibrose. Hyg Med 33:456-462.
Riordan JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui L-C (1989) Identification of the cystic fibrosis gene: cloning and characterization of the complementary DNA. Science 245:1066-1073.
Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD (2004) Characterization of bacterial community diversity in cystic fibrosis lung infections bye use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling.
J Clin Microbiol 42:5176-5183.
Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Kehagia V, Jones GR, Bruce KD (2005) Bacterial activity in cystic fibrosis lung infections. Respir Res 6:49.
Rogers GB, Hoffmann LR, Döring G (2011) Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J Cyst Fibros 10:387-400.
Rommens JM, Iannuzzi MC, Kerem BS, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, Zsiga M, Buchwald M, Riordan JR, Tsui L-C, Collins FS (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping.
Science 245:1059-1065.
Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies D (2002) Anaerobic biofilm infections in cystic fibrosis. J Bacteriol 184:1140-1154.
Schobert M, Jahn D (2010) Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung. Int J Med Microbiol 300:549-556.
Sibley CD, Sibley KA, Leong TA, Grinwis ME, Parkins MD, Rabin HR, Surette MG (2010) The Streptococcus milleri population of a cystic fibrosis clinic reveals patient specificity and intraspecies diversity. J Clin Microbiol 48:2592-2594.
Sibley CD, Surette MG (2011) The polymicrobial nature of airway infections in cystic fibrosis: Cangene Gold Medal Lecture. Can J Microbiol 57:69-77.
47
Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F (2013) Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros 13:152-155.
Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TWV, Carroll MP, Hoffmann LR, Jones G, Allen CE, Patel N, Forbes B, Tuck A, Bruce KD (2011) Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros 10:357-365.
Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TW, Patel N, Forbes B, Bruce KD (2012) Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience, Thorax 67:867-873.
Taccetti G, Bianchini E, Cariani L, Buzzetti R, Constantini D, Trevisan F, Zavataro L, Campana S (2012) Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomized multicentre study comparing two different protocols. Thorax 67:853-859.
Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell E, Elborn JS (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177:995-1001.
Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, Elborn JS, Wolfgang MC (2011) Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis.
Thorax 66:579-584.
Valerius NH, Koch C, Høiby N (1991) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338:725-726.
Van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Daniels TW, Carroll MP, Parkhill J, Bruce KD (2011) Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. The ISME Journal 5:780-791.
48
Vander Wauwen C, Piérard A, Kley-Raymann M, Haas D (1984) Pseudomones aeruginosa mutants affected in anaerobic growth on arginine: evidence of a four-gene cluster encoding the arginine deiminase pathway. J Bacteriol 160:928-934.
Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N, Borneff-Lipp M, Döring G (2009) Antibiotic-resistant obligate anaerobes during exacerbation of cystic fibrosis patients. Clin Microbiol Infect 15:454-460.
Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Döring G (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:317-325.
Yahav D, Farbman L, Leibovici L, Paul M (2012) Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 18:18-29.
Zemanick E, Harris J, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA (2013) Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations, PLoS One 8:e62917.
Zemanick ET, Sagel SD, Harris JK (2011) The airway microbiome in cystic fibrosis and implications for treatment. Current Opinion in Pediatrics 23:319-324.
Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD (2010) Pulmonary exazerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol 45:569-577.
49